文献速递衰弱、肌少症与跌倒老年慢病共病管理

肌少症疾病模型:肌萎缩侧索硬化

Amyotrophic lateral sclerosis as a disease model of sarcopenia.
PubMed 文献 · Age Ageing · 2024-01-01

本文将肌萎缩侧索硬化(ALS)视为肌少症的疾病模型,指出两者虽致病机制有差异,但共享运动单位丢失、肌纤维萎缩、氧化应激、线粒体功能障碍和炎症等特征。老年肌肉组织学表现与ALS患者相似,但ALS患者的肌少症过程长期被忽视,相关文献极少。目前两者均无获批的特异性药物治疗,针对肌肉的肌生成抑制素和mTOR抑制剂正在研究中。

要点

  • ALS与年龄相关肌少症共享运动单位丢失、肌纤维萎缩等特征。
  • 老年肌肉的组织学表现与ALS患者相似。
  • ALS患者的肌少症过程被忽视,相关文献极少。

核心结论

  • ALS可作为肌少症的疾病模型,两者共享运动单位丢失和肌纤维萎缩等特征。
  • ALS患者的肌少症过程被忽视,相关文献极少,但针对肌肉的治疗可能同时惠及ALS患者和老年肌少症患者。

研究设计与样本

  • 本文为综述,未报告系统检索范围。

主要发现

  • ALS与年龄相关肌少症共享运动单位丢失、肌纤维萎缩、氧化应激、线粒体功能障碍和炎症等特征。
  • 老年肌肉组织学显示纤维大小异质性、纤维群组化和卫星细胞丢失,与ALS患者相似。
  • 目前无获批的特异性药物可逆转运动神经元损伤或治愈ALS,肌少症同样无获批药物。
  • 肌生成抑制素和mTOR抑制剂等靶向肌肉的药物正在肌少症和ALS领域研究中。

关键数值与推荐

  • 2010年欧洲老年人肌少症工作组将运动神经元丢失的神经退行性疾病纳入肌少症机制。
  • 部分用于评估老年人肌少症的工具也可用于ALS患者。

临床怎么用

  • 可考虑将老年人肌少症的评估工具应用于ALS患者。
  • 关注靶向肌肉的治疗在ALS和老年肌少症中的研究进展。

局限性

  • 本文为综述,未报告系统检索策略。
  • ALS患者肌少症相关文献非常稀缺。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sarcopenia, the progressive decline of muscle mass and function, has traditionally been viewed as an age-related process leading to a broad range of adverse outcomes. However, it has been widely reported that sarcopenia can occur earlier in life in association with various conditions (i.e. disease-related sarcopenia), including neuromuscular disorders. As early as 2010, the European Working Group on Sarcopenia in Older People included neurodegenerative diseases characterised by motor neuron loss among the mechanisms underlying sarcopenia. Despite some differences in pathogenetic mechanisms, both amyotrophic lateral sclerosis (ALS) and age-related sarcopenia share common characteristics, such as the loss of motor units and muscle fibre atrophy, oxidative stress, mitochondrial dysfunction and inflammation. The histology of older muscle shows fibre size heterogeneity, fibre grouping and a loss of satellite cells, similar to what is observed in ALS patients. Regrettably, the sarcopenic process in ALS patients has been largely overlooked, and literature on the condition in this patient group is very scarce. Some instruments used for the assessment of sarcopenia in older people could also be applied to ALS patients. At this time, there is no approved specific pharmacological treatment to reverse damage to motor neurons or cure ALS, just as there is none for sarcopenia. However, some agents targeting the muscle, like myostatin and mammalian target of rapamycin inhibitors, are under investigation both in the sarcopenia and ALS context. The development of new therapeutic agents targeting the skeletal muscle may indeed be beneficial to both ALS patients and older people with sarcopenia.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Azzolino D, Piras R, Zulueta A, et al. Amyotrophic lateral sclerosis as a disease model of sarcopenia. Age Ageing. 2024. PMID: 39311426. doi:10.1093/ageing/afae209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。